PhenoNet is Rethinking Neurodegenerative Disease Treatment

Early and late-stage intervention trials were conducted when the brain was already compromised with subjects having mixed genetic subgroups, resulting in a series of failed trials.

Early-stage, Disease modifying treatment design for the 60% of Alzheimer's patients without the APOE4 gene variant.